Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
In March 2025, multiple member associations in the Asia Pacific region, including Australia, India, Japan, New Zealand, Philippines, Thailand and Taiwan conducted and participated in crucial online webinars to drive forward knowledge and expertise, helping to improve the lives of those living with dementia in the region.
ADI Asia Pacific Regional Director , DY Suharya, attended and supported two crucial cross-sectional meetings in both Malaysia and Maldives. These timely meetings brought researchers, policymakers and medical practitioners together to pave the way for the development of a new National Dementia Plan in Maldives and an important strategic deployment meeting around the newly launched plan in Malaysia.